Zeneris Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-12-2024
- Paid Up Capital ₹ 0.10 M
as on 08-12-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 549.04%
(FY 2021)
- Profit 2596.77%
(FY 2021)
- Ebitda 3340.53%
(FY 2021)
- Net Worth 9411.53%
(FY 2021)
- Total Assets 332.14%
(FY 2021)
About Zeneris Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rashi Dixit and Aditya Agrawal serve as directors at the Company.
- CIN/LLPIN
U33100DL2016PTC302689
- Company No.
302689
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jul 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Zeneris Pharma Private Limited offer?
Zeneris Pharma Private Limited offers a wide range of products and services, including Surgical & ICU Equipments, Oxygen Cylinder, Medical Treatment Services, Asthma Treatment Services, Herbal & Ayurvedic Medical Services, Ayurvedic Treatment, Healthcare Devices, Oximeters & Pedometers, Oxygen Concentrators & Cans, Health Conditions.
Who are the key members and board of directors at Zeneris Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rashi Dixit  | Additional Director | 30-Mar-2024 | Current |
| Aditya Agrawal | Director | 08-Jul-2016 | Current |
Financial Performance of Zeneris Pharma.
Zeneris Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 549.04% increase. The company also saw a substantial improvement in profitability, with a 2596.77% increase in profit. The company's net worth Soared by an impressive increase of 9411.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zeneris Pharma?
In 2021, Zeneris Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Universal Industrial Plants Mfg.Co. Private LimitedActive 38 years 3 monthsAditya Agrawal is a mutual person
Universal Ing.La.Boschi Plants Private LimitedActive 5 years 5 monthsAditya Agrawal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zeneris Pharma?
Unlock and access historical data on people associated with Zeneris Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zeneris Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zeneris Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
